Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part II: An Application in a clinical trial of unresectable non-small-cell lung cancer

Statistics in Medicine

Volumn 23, Issue 13, 2004, Pages 2005-2022

  Yamaguchi, Takuhiro ^a   Ohashi, Yasuo ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cancer clinical trials; Causal inference; Direct effect; ITT analysis; Post randomization variables; Second line treatment

Indexed keywords

CISPLATIN; DOCETAXEL; IFOSFAMIDE; IRINOTECAN; NAVELBINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANOREXIA; ARTICLE; BASOPHILIA; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER STATISTICS; CANCER SURVIVAL; CANCER THERAPY; CLINICAL OBSERVATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; ENTEROCOLITIS; EOSINOPENIA; EOSINOPHILIA; ERYTHROPENIA; FEMALE; FEVER; HEMATURIA; HUMAN; HYPERCHLOREMIA; HYPERPHOSPHATEMIA; HYPOCALCIURIA; HYPOCHLOREMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INFECTION; KIDNEY DYSFUNCTION; LEUKOPENIA; LIVER DYSFUNCTION; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MONOCYTOSIS; NAUSEA AND VOMITING; NEUTROPENIA; PARESTHESIA; PHASE 3 CLINICAL TRIAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; STATISTICAL MODEL; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; JAPAN; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 3242784185     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.1817     Document Type: Article

References (19)

1. ASCO Non-small-cell Lung Cancer Expert Panel. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by American Society of Clinical Oncology. Journal of Clinical Oncology 1997; 15(8):2996-3018.
2. Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. Journal of Clinical Oncology 2000; 18(21):3722-3730.
3. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L, TAX 320 Non-Small-Cell Lung Cancer Study Group. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The Tax 320 Non-Small-Cell Lung Cancer Study Group. Journal of Clinical Oncology 2000; 18(12):2354-2362.
4. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncoloqy 2000; 18(10):2095-2103.
5. Negoro S, Masuda N, Takada Y, Sugiura T, Kudoh S, Katakami N, Ariyoshi Y, Ohashi Y, Niitani H, Fukuoka M for the CPT-11 Lung Cancer Study Group West. Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. British Journal of Cancer 2003; 88:335-341.
6. Pazdur R. Response rates, survival, and chemotherapy trials. Journal of the National Cancer Institute 2000; 92(19):1552-1553.
7. Robins JM, Greenland S. Adjusting for differential rates of prophylaxis therapy for PCP in high- versus low-dose AZT treatment arms in an AIDS randomized trial. Journal of the American Statistical Association 1994; 89:737-49.
8. Yamaguchi T, Ohashi Y. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: Structural nested models and marginal structural models to test and estimate treatment arm effects. Statistics in Medicine 2004; 23:1991-2003.
9. Robins JM. Structural nested failure time models. Encyclopedia of Biostatistics. Wiley: Chichester, 1998; 4372-4389.
10. Robins JM. Marginal structural models versus structural nested models as tools for causal inference. Statistical Models in Epidemiology, The Environment, and Clinical Trials. Springer: New York, 1999; 95-133.
11. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-560.
12. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-570.
13. Robins JM. Causal inference from complex longitudinal data. Latent Variable Modeling and Applications to Causality. Springer: New York, 1997; 69-117.
14. Lagakos SW, Lim LL-Y, Robins JM. Adjusting for early treatment termination in comparative clinical trials. Statistics in Medicine 1990; 9:1417-1424.
15. Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. Controlled Clinical Trials 1993; 14:79-97.
16. SAS Institute Inc. SAS/IML Software: Change and Enhancements through Release 6.11. SAS Institute Inc: Cary, NC, 1995.
17. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Custom O, Sergysels R, Mommen P, Klastersky J. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. Journal of Clinical Oncology 1995; 13(5):1221-1230.
18. Robins JM. Estimation of the time-dependent accelerated failure time model in the presence of confounding factors. Biometrika 1992; 79:321-332.
19. Robins JM, Mark SD, Newey WK. Estimating exposure effects by modelling the expectation of exposure conditional on confounders. Biometrics 1992; 48:479-495.